NCT00622063View on ClinicalTrials.gov

An Extension Study for Patients Previously Treated With ARQ 501

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

1

Participants

Timeline

Start Date

December 31, 2006

Primary Completion Date

September 30, 2008

Conditions
Cancer
Interventions
DRUG

ARQ 501

Treatment with ARQ 501 or ARQ 501 as combination therapy at the dose and regimen previously received

Trial Locations (1)

75246

Mary Crowley Medical Research Center, Dallas

All Listed Sponsors
lead

ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)

INDUSTRY

NCT00622063 - An Extension Study for Patients Previously Treated With ARQ 501 | Biotech Hunter | Biotech Hunter